0:01

So how I approach the reporting cases of follow up.

0:04

First, I will always open the baseline PET CT to get a sense

0:09

of where the extent of disease was at the beginning

0:12

and how it has changed over time.

0:15

Then in the body of my report, I will specify the

0:20

novel groups that are involved,

0:22

but I will only provide measurements

0:25

both in centimeters

0:27

and SUV max for representative examples.

0:32

And I will include for sure the areas of highest uptake

0:37

because not necessarily will be the areas

0:41

of larger disease.

0:44

So I will include the adenopathy

0:47

or areas of higher FDG uptake

0:50

and also we'll include the areas

0:52

that are larger on the CT portion of the study.

0:56

It's always important to mention if there is extra novel

0:59

disease, and as I explain in the body

1:02

of the report the changes,

1:05

I will describe both changes in intensity of uptake

1:08

and changes in size.

1:10

This is important because lymphoma is one of those diseases

1:14

that may have residual treated

1:19

disease, and this doesn't mean that there is active disease.

1:23

That's the power of FDG in lymphoma is that it's able

1:27

to identify areas of active disease

1:30

because it has FDG uptake as opposed

1:33

to following up on CT where the treated noal mass

1:37

or extra nodal disease may be stable over time.

1:43

In the body of the report I will describe

1:45

how is the uptake relative to the blood pool or mein

1:50

and liver, so the clinician as they read,

1:54

can start getting an idea of the final de will score

1:58

and in the impression, aside from the overall read,

2:03

if there is improvement or progression

2:05

or a mix, I will always add the DE score.

Role of FDG PET/CT Imaging in Lymphoma: Follow-up Reports

HIDE

Prev Next

Interactive Transcript

Pro Tip: Click on a word in the transcript to jump to that point in the video

0:01

So how I approach the reporting cases of follow up.

0:04

First, I will always open the baseline PET CT to get a sense

0:09

of where the extent of disease was at the beginning

0:12

and how it has changed over time.

0:15

Then in the body of my report, I will specify the

0:20

novel groups that are involved,

0:22

but I will only provide measurements

0:25

both in centimeters

0:27

and SUV max for representative examples.

0:32

And I will include for sure the areas of highest uptake

0:37

because not necessarily will be the areas

0:41

of larger disease.

0:44

So I will include the adenopathy

0:47

or areas of higher FDG uptake

0:50

and also we'll include the areas

0:52

that are larger on the CT portion of the study.

0:56

It's always important to mention if there is extra novel

0:59

disease, and as I explain in the body

1:02

of the report the changes,

1:05

I will describe both changes in intensity of uptake

1:08

and changes in size.

1:10

This is important because lymphoma is one of those diseases

1:14

that may have residual treated

1:19

disease, and this doesn't mean that there is active disease.

1:23

That's the power of FDG in lymphoma is that it's able

1:27

to identify areas of active disease

1:30

because it has FDG uptake as opposed

1:33

to following up on CT where the treated noal mass

1:37

or extra nodal disease may be stable over time.

1:43

In the body of the report I will describe

1:45

how is the uptake relative to the blood pool or mein

1:50

and liver, so the clinician as they read,

1:54

can start getting an idea of the final de will score

1:58

and in the impression, aside from the overall read,

2:03

if there is improvement or progression

2:05

or a mix, I will always add the DE score.

Report

Faculty

Elisa Franquet Elia, MD

Assistant Professor of Radiology

UMass Chan Medical School

Lesson

Introduction to PET/CT Imaging

Lesson

FDG Use in PET/CT

Lesson

FDG: Common Pitfalls and Benign Lesions

Lesson

FDG Use in Hematologic Malignancies

Lesson

FDG Use in Lung Cancer

Lesson

FDG Use in Head & Neck Cancer

Lesson

FDG Use in Breast Cancer

Lesson

FDG Use in Immunotherapy

Lesson

DOTATATE Use in PET/CT

Lesson

DOTATATE and FDG Use in Neuroendocrine Tumors

Lesson

PSMA Use in PET/CT

Lesson

PSMA Use in Prostate Cancer

Role of FDG PET/CT Imaging in Lymphoma: Follow-up Reports